Is there justification for universal leukoreduction?  by Mendrone, Alfredo et al.
EI
A
C
J
T
T
T
A
l
s
a
c
b
u
s
d
f
w
r
c
h
1
rrev bras hematol hemoter. 2014;36(4):237
Revista Brasileira de Hematologia e Hemoterapia
Brazilian Journal of Hematology and Hemotherapy
www.rbhh.org
ditorial
s there justiﬁcation for universal leukoreduction?
lfredo Mendrone Jr., Antonio Fabron Jr., Dante Langhi Jr., Dimas Tadeu Covas,
arla Luana Dinardo, Eugênia Amorim Ubiali, José Francisco Comenalli Marques Jr. ∗,
osé Orlando Bordin, Marilia Rugani
ransfusion Medicine Committee, Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular, Rio de Janeiro, RJ, Brazilhe Associac¸ão Brasileira de Hematologia, Hemoterapia e
erapia Celular (ABHH), the institution that represents the
ssociac¸ão Médica Brasileira (AMB) in respect to hemato-
ogy, transfusion therapy and cell therapy in Brazil hereby
tates:
Prospective randomized studies have not demonstrated
ny positive clinical impact with the universal use of blood
omponents in which the initial number of leukocytes has
een reduced (universal leukoreduction). For this reason,
niversal leukoreduction remains a technically controver-
ial topic. The current consensus is that leukoreduction has
eﬁned indications in the prevention of three blood trans-
usion complications only: (i) non-hemolytic febrile reactions
hen the patient has had this reaction previously; (ii) platelet
efractoriness caused by alloimmunization against leuko-
yte antigens and (iii) the transmission of cytomegalovirus
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eserved.(CMV) in susceptible patients (according to Brazilian Leg-
islation). In these three situations, as a clinically effective
precaution, patients should receive leukoreduced blood com-
ponents. Other beneﬁts proposed for leukoreduction such as
decreased transmission of prions (which is the reason some
European countries implemented universal leukoreduction
a few years ago), reducing the occurrence of transfusion-
related immunomodulation (TRIM), as an effort to stop the
progression of cancer and reduce transfusion-related bacterial
infection rates remain controversial with contradictory results
of studies.
Thus, the interpretation of current evidence shows no ben-
eﬁts of leukoreduction besides the three above-mentioned
indications.
Hence, universal leukoreduction is not technically justiﬁed
and its use is not advocated by the ABHH.
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